Fluphenazine Enanthate
This medium-acting injectable ester form of fluphenazine provides sustained release of the antipsychotic medication over approximately one to two weeks. It is used in patients with schizophrenia who require regular antipsychotic coverage without daily oral dosing.
Peso molecular
549,7000 g/mol
LogP
7,40
TPSA
61,30 Ų
Regla de cinco de Lipinski
No cumple
Mecanismo de acción
Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …
Estructura 2D
Cite this structure
Embed this structure
SMILES
CCCCCCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1
InChI
InChI=1S/C29H38F3N3O2S/c1-2-3-4-5-11-28(36)37-21-20-34-18-16-33(17-19-34)14-8-15-35-24-9-6-7-10-26(24)38-27-13-12-23(22-25(27)35)29(30,31)32/h6-7,9-10,12-13,22H,2-5,8,11,14-21H2,1H3
Molecular Formula
C29H38F3N3O2S
HBD / HBA
- / 9
Enlaces Rotables
13
Átomos Pesados
38
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
This medium-acting injectable ester form of fluphenazine provides sustained release of the antipsychotic medication over approximately one to two weeks. It is used in patients with schizophrenia who require regular antipsychotic coverage without daily oral dosing.
Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.
Yes, Fluphenazine Enanthate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200951. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 3389. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="fluphenazine-enanthate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/fluphenazine-enanthate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/fluphenazine-enanthate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/fluphenazine-enanthate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="fluphenazine-enanthate"></drugfyi-drug>